Efficacy and Tolerability of Lopinavir/Ritonavir- and Efavirenz-Based Initial Antiretroviral Therapy in HIV-1-Infected Patients in a Tertiary Care Hospital in Beijing, China

Advanced HIV: diagnosis, treatment, and prevention

(2019) Sandeep Prabhu et al.   Lancet HIV

Early antiretroviral therapy on reducing HIV transmission in China: strengths, weaknesses and next focus of the program

(2018) Pengtao Liu et al.   Scientific Reports

Protease Inhibitors or NNRTIs as First-Line HIV-1 Treatment in West Africa (PIONA)

(2018) Sanne Jespersen et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

HIV

(2018) Jade Ghosn et al.   LANCET

Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies

(2017) Adam Trickey et al.   Lancet HIV

The trend of transmitted drug resistance in newly diagnosed antiretroviral-naive HIV/AIDS patients during 1999–2012 in South Korea

(2016) Mina Park et al.   JOURNAL OF CLINICAL VIROLOGY

Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS

(2016) Arun K. Ghosh et al.   JOURNAL OF MEDICINAL CHEMISTRY

Predictors of Treatment Failure among Adult Antiretroviral Treatment (ART) Clients in Bale Zone Hospitals, South Eastern Ethiopia

(2016) Demewoz Haile et al.   PLoS One

Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015

(2016) Haidong Wang et al.   Lancet HIV

Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women

(2015) Deborah Cohan et al.   AIDS

Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230

(2015) N. Kumarasamy et al.   CLINICAL INFECTIOUS DISEASES

CD4 Response Up to 5 Years After Combination Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Patients in Latin America and the Caribbean: Figure 1.

(2015) Paula M. Luz et al.   Open Forum Infectious Diseases

Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection

(2015) Xianmin Meng et al.   PLoS One

Antiretroviral Treatment of Adult HIV Infection

(2014) Huldrych F. Günthard et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Boosted lopinavir vs boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in Kampala

(2014) Eva Laker et al.   Journal of the International AIDS Society

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

(2013) Neil J. Stone et al.   CIRCULATION

Resistance at Virological Failure Using Boosted Protease Inhibitors Versus Nonnucleoside Reverse Transcriptase Inhibitors As First-Line Antiretroviral Therapy—Implications for Sustained Efficacy of ART in Resource-Limited Settings

(2013) Andrew Hill et al.   JOURNAL OF INFECTIOUS DISEASES

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

(2013) Neil J. Stone et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis

(2012) Ravindra K Gupta et al.   LANCET

A Once-Daily Lopinavir/Ritonavir-Based Regimen Is Noninferior to Twice-Daily Dosing and Results in Similar Safety and Tolerability in Antiretroviral-Naive Subjects Through 48 Weeks

(2009) Joseph Gathe et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES